38937-66-5

Suberohydroxamic acid (SBHA) is a competitive histone deacetylase (HDAC) inhibitor that has been shown to inhibit HDAC1 (IC50 = 0.25 μM) and HDAC3 (IC50 = 0.30 μM). SBHA causes cell differentiation, cell cycle arrest, or apoptosis. HDAC inhibitors, including SBHA, act synergistically to kill cancer cells when used in combination with cytostatic drugs, allowing lower doses of both inhibitors and drugs to be used.

Histone deacetylase inhibitor. A cell-permeable inhibitor of HDAC1 and HDAC3. Shown to suppresses the growth of proliferating keratinocytes and squamous cell carcinoma cells.

Inhibits histone deacetylation.

ChEBI: N,N'-dihydroxyoctanediamide is a hydroxamic acid.

Induces cellular differentiation. Inhibits histone deacetylation.

Suberoyl bis-hydroxamic acid (SBHA) is a Histone deacetylase (HDAC) inhibitor. SBHA inhibits the activity of HDAC1 and HDAC3 with IC50 values of 250 and 300 nM, respectively. SBHA inhibits proliferation, and induces apoptosis in several cancer cell lines. SBHA has been shown to activate Notch signaling in medullary thyroid carcinoma (MTC) cells.

1. richon vm, emiliani s, verdin e et al. a class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. proc natl acad sci u s a. 1998 mar 17; 95(6):3003-7.2. zhang xd, gillespie sk, borrow jm, hersey p. the histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. mol cancer ther. 2004 apr; 3(4):425-35.